Vinca alkaloid cytotoxic

Vindesine sulfate (Specialist drug)

Vindesine sulfate is a vinca alkaloid cytotoxic administered intravenously for certain leukaemias and solid tumours.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds tubulin and inhibits microtubule assembly, halting cell division at metaphase.

Prescribing in practice

It is for intravenous use only and is fatal if given intrathecally; spinal-injection safety procedures must be followed.
Myelosuppression and peripheral neuropathy are the main dose-limiting toxicities.
It is a vesicant specialist cytotoxic requiring extravasation precautions and expert oversight.

Monitoring

Monitor full blood count before dosing and assess regularly for peripheral neuropathy and signs of infection.

Counselling the patient

Report signs of infection such as fever or sore throat without delay.
Report numbness, tingling or muscle weakness.
Alert staff immediately to any pain or swelling at the injection site.

Evidence & guidelines

Its use is supported by established chemotherapy practice within specialist oncology services.

Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Pathways